trending Market Intelligence /marketintelligence/en/news-insights/trending/h7G6e0a81qQrywo7RCG_EQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aldeyra Therapeutics seeks US FDA approval after dry eye drug clears trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aldeyra Therapeutics seeks US FDA approval after dry eye drug clears trial

Aldeyra Therapeutics Inc. will explore regulatory approval for reproxalap after the dry eye therapy reduced itching associated with allergic conjunctivitis in patients during a late-stage clinical trial.

The phase 3 clinical trial, called Alleviate, examined two doses of reproxalap topical ophthalmic solution in 318 patients with seasonal allergic conjunctivitis. The condition can cause dry eye, itching and redness after exposure to seasonal allergens. The trial's main goal was to reduce itching after exposure to an allergen, and the secondary goal was to determine patients' response to the therapy.

Reproxalap was found to be superior to standard antihistamine treatment in reducing inflammation and itching during the trial.

The therapy has previously been evaluated in five mid-stage clinical trials, but the Alleviate trial marks the first successful results in phase 3.

Aldeyra said in a March 26 press release that the positive results mean the Lexington, Mass.-based company will meet with the U.S. Food and Drug Administration in the second quarter to discuss submission of a new drug application for reproxalap.

Chief Medical Officer David Clark said that reproxalap could complement existing therapies for seasonal allergic conjunctivitis and allow patients to avoid progressing to corticosteroids, which he said can lead to ocular toxicity.

Reproxalap is also being developed for several other eye conditions, including dry eye disease.